Peripheral Neuropathy Trial, Recruiting (NCT06615622)

Peripheral Neuropathy Trial, Recruiting NCT06615622 Sponsor: Assiut University Condition: Peripheral Neuropathy

Printed from Voxsanity (voxsanity.com.au) — NCT06615622 — Data sourced from ClinicalTrials.gov. Verify directly with the trial site before attending. Not medical advice.

Back to Peripheral Neuropathy

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

People who have been diagnosed with Guillain-Barré Syndrome (GBS) according to recognised international diagnostic guidelines, or people diagnosed with Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) according to European neurological society guidelines.
People aged between 18 and 75 years old.
For GBS: People whose symptoms started within the last 2 weeks. For CIDP: People whose condition either comes and goes in episodes, or is slowly getting worse over time.
Both men and women are eligible to join.
People who are willing to take part in study-related check-ups and assessments.
People who are able to understand and willing to sign an informed consent form agreeing to take part.

Who may not be able to join:

People who are unable or unwilling to sign an informed consent form.
People who have metabolic disorders or any form of cancer.
People whose nerve damage is caused by something other than GBS or CIDP.
People whose muscle weakness or paralysis is caused by a condition other than GBS or CIDP.

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.

Last synced 22 July 2026

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Phone: +201022748859

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Voxsanity

Clinical trials and treatments, explained plainly · voxsanity.com.au

Date:

To: My Doctor

Re: Clinical trial enquiry

I am writing to enquire about the following clinical trial which may be relevant to my care:

Trial: NCT06615622

Sponsor: Assiut University

Phase: Not Applicable

Status: Recruiting

Condition: Peripheral Neuropathy

Trial contact: +201022748859

More information: https://clinicaltrials.gov/study/NCT06615622

Eligibility summary (AI generated)

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

People who have been diagnosed with Guillain-Barré Syndrome (GBS) according to recognised international diagnostic guidelines, or people diagnosed with Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) according to European neurological society guidelines.
People aged between 18 and 75 years old.
For GBS: People whose symptoms started within the last 2 weeks. For CIDP: People whose condition either comes and goes in episodes, or is slowly getting worse over time.
Both men and women are eligible to join.
People who are willing to take part in study-related check-ups and assessments.
People who are able to understand and willing to sign an informed consent form agreeing to take part.

Who may not be able to join:

People who are unable or unwilling to sign an informed consent form.
People who have metabolic disorders or any form of cancer.
People whose nerve damage is caused by something other than GBS or CIDP.
People whose muscle weakness or paralysis is caused by a condition other than GBS or CIDP.

Important: Always verify eligibility with the trial site directly before applying.

Access in Australia: A treatment being studied in a clinical trial is generally not yet listed on the PBS. Where a medicine is not approved or not available through a trial, the TGA Special Access Scheme may allow a doctor to access unapproved therapeutic goods for individual patients. See voxsanity.com.au/sas-navigator/ for a plain English explainer.

This information was sourced from ClinicalTrials.gov via Voxsanity (data last synced 22 July 2026). It is not medical advice. Please verify the trial's current status directly with the trial site before acting.

Trial details

Status

Recruiting

Phase

Not Applicable

Sponsor

Assiut University

Registry

ClinicalTrials.gov

Start date

1 September 2024

Est. completion

30 March 2027

Where this trial is recruiting

🇪🇬 Egypt

Primary endpoints

Detection of Nerve Alterations via Ultrasound

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 22 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov